Movement Alert｜Pharmaron Rises 5.93% in Regular Trading, Daiwa Initiates Coverage with Buy Rating and HK$25.5 Target

Market Focus07-10

On July 10, Pharmaron (03759.HK) rose 5.93% in regular trading, trading at HK$21.6/share, with turnover of HK$62.87 million.

On the news front, Daiwa recently initiated coverage on Pharmaron H-shares with a Buy rating and a target price of HK$25.5, implying approximately 18% upside from the current price. Daiwa noted that the company benefits from the recovery in global biopharma financing and sustained outsourcing demand from multinational pharmaceutical and biotech clients. The brokerage expects the laboratory services segment to grow 13-15% in revenue from 2026 to 2028, while the CMC business is projected to achieve a 24% compound annual growth rate over the same period as it moves toward commercialization.

Daiwa highlighted that Pharmaron's new order signings grew over 30% year-over-year in Q1, supporting confidence in the company's full-year revenue growth guidance of 12-18%. Within the Life Sciences Tools and Services sector, peers also posted gains, with WuXi AppTec up 4.70%, WuXi Bio up 4.37%, and WuXi XDC up 3.03%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105535740?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 10:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105535740","market":"us","top_or_hot":-1,"title":"Movement Alert｜Pharmaron Rises 5.93% in Regular Trading, Daiwa Initiates Coverage with Buy Rating and HK$25.5 Target","media":"Market Focus","content":"<p><p>On July 10, Pharmaron (03759.HK) rose 5.93% in regular trading, trading at HK$21.6/share, with turnover of HK$62.87 million.</p><p>On the news front, Daiwa recently initiated coverage on Pharmaron H-shares with a Buy rating and a target price of HK$25.5, implying approximately 18% upside from the current price. Daiwa noted that the company benefits from the recovery in global biopharma financing and sustained outsourcing demand from multinational pharmaceutical and biotech clients. The brokerage expects the laboratory services segment to grow 13-15% in revenue from 2026 to 2028, while the CMC business is projected to achieve a 24% compound annual growth rate over the same period as it moves toward commercialization.</p><p>Daiwa highlighted that Pharmaron's new order signings grew over 30% year-over-year in Q1, supporting confidence in the company's full-year revenue growth guidance of 12-18%. Within the Life Sciences Tools and Services sector, peers also posted gains, with WuXi AppTec up 4.70%, WuXi Bio up 4.37%, and WuXi XDC up 3.03%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Pharmaron Rises 5.93% in Regular Trading, Daiwa Initiates Coverage with Buy Rating and HK$25.5 Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Pharmaron Rises 5.93% in Regular Trading, Daiwa Initiates Coverage with Buy Rating and HK$25.5 Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-10 10:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 10, Pharmaron (03759.HK) rose 5.93% in regular trading, trading at HK$21.6/share, with turnover of HK$62.87 million.</p><p>On the news front, Daiwa recently initiated coverage on Pharmaron H-shares with a Buy rating and a target price of HK$25.5, implying approximately 18% upside from the current price. Daiwa noted that the company benefits from the recovery in global biopharma financing and sustained outsourcing demand from multinational pharmaceutical and biotech clients. The brokerage expects the laboratory services segment to grow 13-15% in revenue from 2026 to 2028, while the CMC business is projected to achieve a 24% compound annual growth rate over the same period as it moves toward commercialization.</p><p>Daiwa highlighted that Pharmaron's new order signings grew over 30% year-over-year in Q1, supporting confidence in the company's full-year revenue growth guidance of 12-18%. Within the Life Sciences Tools and Services sector, peers also posted gains, with WuXi AppTec up 4.70%, WuXi Bio up 4.37%, and WuXi XDC up 3.03%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1105535740","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105535740","pubTimestamp":1783648974,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 10, Pharmaron (03759.HK) rose 5.93% in regular trading, trading at HK$21.6/share, with turnover of HK$62.87 million.On the news front, Daiwa recently initiated coverage on Pharmaron H-shares...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"走势警报|康龙化成常规交易涨5.93%，大和给予买入评级，目标价25.5港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"On July 10, Pharmaron (03759.HK) rose 5.93% in regular trading, trading at HK$21.6/share, with turnover of HK$62.87 million.On the news front, Daiwa recently initiated coverage on Pharmaron H-shares with a Buy rating and a target price of HK$25.5, implying approximately 18% upside from the current price. Daiwa noted that the company benefits from the recovery in global biopharma financing and sustained outsourcing demand from multinational pharmaceutical and biotech clients. The brokerage expects the laboratory services segment to grow 13-15% in revenue from 2026 to 2028, while the CMC business is projected to achieve a 24% compound annual growth rate over the same period as it moves toward commercialization.Daiwa highlighted that Pharmaron's new order signings grew over 30% year-over-year in Q1, supporting confidence in the company's full-year revenue growth guidance of 12-18%. Within the Life Sciences Tools and Services sector, peers also posted gains, with WuXi AppTec up 4.70%, WuXi Bio up 4.37%, and WuXi XDC up 3.03%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105535740","isCrawlerRequest":true}